Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer.

e12517Background: HER2-positive breast cancers have a higher risk of recurrence, though systemic chemotherapy in combination with HER2-targeted agents significantly reduces this risk. Neratinib (N)...